Non-Alcoholic Fatty Liver Disease

• Hepatic lipid accumulation via insulin resistance and de novo lipogenesis (DNL): The primary defect in NAFLD involves hepatic insulin resistance with preserved peripheral glucose uptake, leading to paradoxical hyperinsulinemia despite acceptable fasting glucose levels. Insulin normally suppresses hepatic acetyl-CoA carboxylase (ACC) and promotes fatty acid oxidation via AMP-activated protein kinase (AMPK) activation; insulin resistance disrupts this inhibition. Simultaneously, hyperinsulinemia drives increased hepatic de novo lipogenesis through upregulation of sterol regulatory element-binding protein (SREBP-1c), the master transcription factor for fatty acid and triglyceride synthesis. Insulin resistance also impairs fatty acid oxidation through decreased expression of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), reducing mitochondrial β-oxidation capacity. The net result is triglyceride accumulation as lipid droplets within hepatocytes, exceeding the threshold for steatosis. Additionally, increased lipolysis in insulin-resistant adipose tissue elevates free fatty acids (FFAs) reaching the liver, which undergo re-esterification to triglycerides. This "lipid overload" sets the stage for disease progression.

• Oxidative stress, mitochondrial dysfunction, and lipotoxicity driving hepatocellular injury: Once hepatic steatosis is established, accumulated lipids—particularly toxic lipid species including diacylglycerols, lysophosphatidic acids, and oxidized fatty acids—trigger lipotoxicity. These species accumulate within mitochondria, impairing electron transport chain function and increasing the production of reactive oxygen species (ROS), particularly from the β-oxidation of excess fatty acids in peroxisomes and mitochondria. Elevated ROS overwhelms intrinsic antioxidant defenses (glutathione, superoxide dismutase, catalase), leading to lipid peroxidation and formation of toxic lipid peroxides and malondialdehyde. Mitochondrial ROS also triggers opening of the mitochondrial permeability transition pore, releasing cytochrome c and activating apoptosis. This hepatocellular injury and death (particularly through apoptosis and necrosis) characterizes the transition from simple steatosis to NASH. The degree of ROS production correlates with disease severity; hepatocytes with excessive ROS undergo autophagy, which paradoxically can propagate injury through release of cellular contents. Mitochondrial β-oxidation capacity inversely correlates with hepatic fat content, creating a self-perpetuating cycle of lipid accumulation and oxidative injury.

• Endoplasmic reticulum stress and unfolded protein response (UPR) dysregulation: The excessive lipid burden and oxidative stress disrupt normal endoplasmic reticulum (ER) homeostasis, triggering ER stress characterized by accumulation of misfolded proteins. This initiates the unfolded protein response (UPR) through activation of three major sensors: inositol-requiring enzyme 1α (IRE1α), protein kinase RNA-like ER kinase (PERK), and activating transcription factor 6 (ATF6). While the UPR initially attempts to restore ER function through increased chaperone expression and reduced translation, persistent ER stress leads to dysregulated UPR signaling that promotes hepatocellular apoptosis through CHOP (C/EBP homologous protein) activation and JNK phosphorylation. ER stress also augments the production of hepatic apolipoprotein B100, promoting VLDL secretion and worsening dyslipidemia. Prolonged UPR activation characterizes NASH, differentiating it from benign steatosis where ER stress is minimal. This mechanism explains the therapeutic potential of ER stress-reducing interventions.

• Hepatic inflammation, macrophage infiltration, and fibrogenesis: The hepatocellular injury and ROS-mediated damage activate pattern recognition receptors (TLRs, particularly TLR4 and TLR9) on hepatic macrophages (Kupffer cells) and infiltrating monocytes, triggering a pro-inflammatory response characterized by increased TNF-α, IL-6, and IL-1β production. Additionally, hepatocyte-derived damage-associated molecular patterns (DAMPs), including extracellular ATP and mitochondrial DNA, activate Kupffer cells and promote the inflammasome pathway through NLRP3, amplifying IL-1β and IL-18 secretion. This pro-inflammatory milieu recruits additional immune cells and triggers hepatic stellate cell (HSC) activation—a critical step in fibrogenesis. Activated HSCs (myofibroblasts) produce excess collagen I and III, replacing normal hepatic parenchyma with fibrotic tissue. HSCs are activated both through direct signaling (TGF-β from injured hepatocytes, macrophage-derived cytokines) and through paracrine effects of hepatocyte apoptosis, which releases pro-fibrotic signals. The degree of Kupffer cell infiltration and TNF-α/IL-6 expression predicts progression to fibrosis and correlates with NASH severity. This inflammatory-fibrotic axis explains why simple steatosis can progress to NASH and, in a subset of patients, to cirrhosis.

• Genetic and epigenetic modulation of disease susceptibility: Multiple genetic variants influence NAFLD susceptibility and severity independent of obesity or metabolic syndrome. The most well-characterized is the PNPLA3 (patatin-like phospholipase domain-containing 3) I148M polymorphism, where the minor G allele (encoding methionine at position 148) is associated with increased hepatic fat content and progression to NASH and fibrosis in multiple ethnic groups. PNPLA3 encodes adiponutrin, a triglyceride hydrolase involved in lipid droplet remodeling; the I148M variant reduces enzyme activity, impairing hepatic lipid turnover. Other significant variants include TM6SF2 (transmembrane 6 superfamily member 2), which affects lipid export and VLDL secretion; MBOAT7 (membrane-bound O-acyltransferase 7), involved in phosphatidylinositol remodeling; and HSD17B13 (hydroxysteroid 17-beta dehydrogenase 13), where loss-of-function variants are protective. These genetic variants explain why some individuals develop NASH and advanced fibrosis despite modest obesity or metabolic dysfunction, while others remain relatively protected. Additionally, epigenetic modifications (DNA methylation, histone modifications, microRNA expression) are dysregulated in NAFLD, further modulating disease phenotype and progression.

• Metabolic dysfunction and insulin resistance (primary mechanism in the vast majority): The fundamental driver of NAFLD is hepatic and systemic insulin resistance, occurring in >50% of NAFLD patients and >90% of those with NASH. Insulin resistance is mechanistically central to NAFLD pathogenesis, promoting both hepatic steatosis (via enhanced DNL and reduced fatty acid oxidation) and hepatocellular inflammation. The relationship is bidirectional: insulin resistance promotes NAFLD development, and advancing NAFLD (particularly NASH with fibrosis) worsens systemic insulin resistance through increased hepatic glucose production and inflammatory signaling. Insulin resistance is present irrespective of body mass index, explaining NAFLD occurrence in lean individuals and its absence in some obese subjects. The underlying cause of hepatic insulin resistance involves impaired insulin receptor signaling, increased phosphorylation of insulin receptor substrate-1 (IRS-1), and downstream defects in PI3K/Akt signaling. Chronic inflammation and elevated circulating FFAs perpetuate this insulin signaling defect.

• Obesity and metabolic syndrome components: Central obesity (visceral adipose tissue accumulation) strongly predisposes to NAFLD through multiple mechanisms: increased lipolysis in visceral adipose tissue with enhanced FFA delivery to the liver, production of pro-inflammatory adipokines (TNF-α, IL-6, decreased adiponectin), and establishment of systemic insulin resistance. The prevalence of NAFLD in obese individuals approaches 75%, yet obesity alone is neither necessary nor sufficient for NAFLD development. Type 2 diabetes mellitus increases NAFLD risk substantially (30–40% prevalence) through associated hyperglycemia (promoting DNL), hyperinsulinemia, and glucagon dysregulation. Dyslipidemia—particularly elevated triglycerides and low HDL-cholesterol—associates with NASH severity and fibrosis progression. Hypertension, another metabolic syndrome component, independently correlates with NASH and advanced fibrosis, possibly through oxidative stress and endothelial dysfunction mechanisms. The presence of metabolic syndrome (≥3 of 5 criteria: central obesity, elevated triglycerides, reduced HDL, elevated blood pressure, elevated fasting glucose) significantly increases NASH and fibrosis risk compared to NAFLD without metabolic syndrome.

• Genetic predisposition independent of obesity: As outlined above, specific genetic variants (PNPLA3 I148M, TM6SF2, MBOAT7, HSD17B13) impart substantially increased disease risk and severity. Ethnicity influences genetic NAFLD susceptibility: Hispanic/Latino individuals demonstrate higher NAFLD prevalence and more aggressive disease progression compared to European ancestry individuals, partially attributable to higher PNPLA3 risk allele frequency. East Asian ancestry individuals have lower NAFLD prevalence despite high obesity rates, potentially due to protective allele combinations. These genetic factors explain up to 30% of NAFLD heritability and are independent predictors of progression, making them clinically relevant for risk stratification.

• Nutritional factors and dietary composition: High-fructose and refined carbohydrate consumption directly promote hepatic DNL through fructose-mediated SREBP-1c activation and increased acetyl-CoA availability, independent of total caloric intake. Fructose also generates increased hepatic ROS and can impair hepatic autophagy. Saturated fat and trans fat consumption promotes NASH development through increased lipotoxicity and inflammatory responses compared to unsaturated fat. Conversely, Mediterranean diet patterns and omega-3 polyunsaturated fatty acid (PUFA) supplementation show some protective effects through reduced hepatic inflammation and improved lipid profiles. Soluble fiber intake correlates with reduced hepatic steatosis, possibly through improved glucose control and altered gut microbiota. The Western dietary pattern (high ultra-processed foods, refined carbohydrates, saturated fats, sodium; low fruits, vegetables, whole grains) strongly associates with NASH progression.

• Physical inactivity and sedentary behavior: Low physical activity levels associate with increased NAFLD prevalence and severity independent of weight change, through mechanisms including impaired hepatic insulin sensitivity, reduced mitochondrial oxidative capacity, and altered hepatic lipid metabolism. Even modest increases in physical activity improve hepatic steatosis and can reduce NASH activity without significant weight loss, indicating direct hepatic metabolic benefits. Conversely, metabolically unhealthy obesity—obesity with metabolic dysfunction—carries higher NAFLD and NASH risk than metabolically healthy obesity.

• Secondary NAFLD causes (NAFLD with specific etiology): While not strictly "non-alcoholic" if the specific etiology is identified, several conditions produce NAFLD-like histology:
• Medication-induced steatosis: Corticosteroids (through metabolic dysfunction), antiretroviral agents (nucleoside reverse transcriptase inhibitors, protease inhibitors), tamoxifen, L-asparaginase, methotrexate, and amiodarone can produce hepatic steatosis with or without inflammation.
• Nutritional disorders: Protein malnutrition and essential fatty acid deficiency impair hepatic VLDL secretion, leading to steatosis (distinguished from NAFLD by reduced hepatic triglyceride synthesis).
• Rapid weight loss and bariatric surgery: Paradoxically can transiently worsen hepatic steatosis through rapid mobilization of adipose tissue FFAs and impaired hepatic adaptation, though long-term outcomes generally improve with sustained weight loss.
• Lipodystrophy syndromes: Genetic or acquired loss of adipose tissue capacity leads to ectopic hepatic fat deposition and metabolic dysfunction.

• Absence of symptoms in early disease: The majority of patients with simple hepatic steatosis are completely asymptomatic with normal liver function tests, representing a major diagnostic challenge. Some patients may report nonspecific fatigue or malaise, though these symptoms are indistinguishable from age-matched controls and should not be attributed to NAFLD without exclusion of other etiologies. This asymptomatic phenotype reflects the limited inflammatory burden in simple steatosis and underscores the importance of surveillance imaging in high-risk populations.

• Right upper quadrant discomfort (nonspecific): Some patients with NASH report vague right upper quadrant (RUQ) pain, abdominal discomfort, or heaviness, though these symptoms lack specificity and frequently reflect concurrent conditions (biliary disease, functional dyspepsia) rather than NAFLD per se. The pain is typically described as dull and persistent, without radiation, and is not reproducible on examination. RUQ tenderness on examination is unusual unless advanced cirrhosis with hepatomegaly is present.

• Hepatomegaly: Physical examination may reveal hepatomegaly (palpable liver edge >2 cm below the costal margin), occurring in 40–50% of NASH cases and correlating with degree of hepatic steatosis and inflammation. However, hepatomegaly alone has poor specificity for NAFLD and may reflect other conditions (viral hepatitis, alcoholic liver disease, hematologic malignancy). The liver edge in NAFLD is characteristically smooth and non-tender, distinguishing it from acute hepatitis where tenderness is prominent.

• Stigmata of advanced liver disease (late presentations): Patients presenting with advanced fibrosis or cirrhosis may exhibit classic signs of portal hypertension and hepatic synthetic dysfunction: spider angiomas (arteriolar dilation on trunk), palmar erythema (reddening of palms with blanching centers), ascites (abdominal distention with shifting dullness), splenomegaly, jaundice (scleral and skin icterus indicating hyperbilirubinemia), hepatic encephalopathy (altered mental status, asterixis), and caput medusae (dilated periumbilical veins). These findings indicate decompensated cirrhosis and carry significant morbidity and mortality risk.

• Metabolic comorbidity as clinical clue: Patients with concurrent type 2 diabetes, dyslipidemia, hypertension, and/or obesity should raise clinical suspicion for NAFLD, as these conditions frequently coexist. The presence of metabolic syndrome markedly increases the probability of NASH rather than simple steatosis.

• Disease progression presentations: Some patients present with specific complications reflecting advanced disease: variceal bleeding (hematemesis, melena from esophageal varices), hepatic decompensation with jaundice and coagulopathy, hepatic encephalopathy, spontaneous bacterial peritonitis (fever, ascites worsening), or hepatocellular carcinoma (detected on surveillance imaging or presenting with constitutional symptoms, RUQ mass, or decompensation). These presentations indicate end-stage liver disease and warrant

Initial laboratory pattern

• Aminotransferases: mildly elevated, usually less than 4–5× the upper limit of normal, with ALT > AST (AST/ALT ratio <1). A ratio reversing to >1 suggests either advancing fibrosis or, if ≥2:1, alcohol-related liver disease.
• Normal ALT does not exclude NASH or advanced fibrosis — a frequent stem trap.
• Exclusion panel: hepatitis B and C serologies, iron studies/ferritin (hemochromatosis), ANA/anti-smooth muscle antibody and immunoglobulins (autoimmune hepatitis), ceruloplasmin in patients under ~40 (Wilson disease), alpha-1 antitrypsin level, TSH, and a validated alcohol history (AUDIT-C).

Imaging

• Abdominal ultrasound: first-line, showing a diffusely bright (hyperechoic) liver with loss of portal vein wall definition and posterior beam attenuation; insensitive below roughly 20–30% fat content.
• MRI-PDFF: quantifies hepatic fat fraction; the research and trial standard.

Fibrosis risk stratification (AASLD 2023 Practice Guidance and the AGA Clinical Care Pathway)

• FIB-4 index (age, AST, ALT, platelets) is the recommended first-line non-invasive test. Values <1.3 indicate low risk (use a higher threshold in patients ≥65), 1.3–2.67 indeterminate, and >2.67 high risk for advanced fibrosis. The ADA Standards of Care endorse FIB-4 screening in adults with type 2 diabetes or prediabetes with obesity.
• Second-tier testing for indeterminate/high FIB-4: vibration-controlled transient elastography (FibroScan liver stiffness measurement) or the Enhanced Liver Fibrosis (ELF) test; MR elastography is the most accurate non-invasive modality.

Liver biopsy — gold standard

• Reserved for diagnostic uncertainty or discordant non-invasive tests, and is the only way to distinguish simple steatosis from NASH.
• Findings: macrovesicular steatosis ≥5% of hepatocytes, lobular inflammation, hepatocyte ballooning degeneration, Mallory-Denk bodies, and zone 3 perisinusoidal/pericellular "chicken-wire" fibrosis.
• Graded by the NAFLD Activity Score (NAS) (steatosis + lobular inflammation + ballooning) with separate fibrosis staging F0–F4.

First-line — lifestyle modification (AASLD 2023 Practice Guidance)

• Weight loss is the only intervention that reverses the full histologic spectrum, and the response is dose-dependent: roughly 3–5% total body weight loss improves steatosis, 7–10% improves necroinflammation and can resolve NASH, and ≥10% is associated with fibrosis regression.
• Mediterranean-pattern diet with caloric restriction; eliminate fructose-sweetened beverages.
• Structured aerobic and resistance exercise improves hepatic insulin sensitivity and reduces liver fat even without weight loss.
• Alcohol abstinence is advised, and is mandatory in advanced fibrosis or cirrhosis.

Cardiometabolic risk treatment — the intervention that most reduces mortality

• Statins (e.g., atorvastatin): indicated per ACC/AHA cholesterol guidance and explicitly safe in NAFLD/NASH, including compensated cirrhosis. Withholding a statin because of transaminase elevation is a classic error.
• GLP-1 receptor agonists (e.g., semaglutide) and other weight-directed therapy: preferred glucose-lowering agents in type 2 diabetes with MASLD per the ADA Standards of Care, given weight loss and steatohepatitis benefit.

Liver-directed pharmacotherapy (biopsy-proven NASH)

• Pioglitazone (thiazolidinedione, PPAR-γ agonist): improves steatohepatitis histology; usable with or without type 2 diabetes.
• Vitamin E ~800 IU/day: option for non-diabetic, non-cirrhotic adults with biopsy-proven NASH.
• Resmetirom (liver-directed thyroid hormone receptor-β agonist): FDA-approved for noncirrhotic NASH/MASH with moderate-to-advanced (F2–F3) fibrosis, alongside diet and exercise.

Definitive/surgical

• Metabolic (bariatric) surgery in eligible patients with obesity produces durable NASH resolution and fibrosis improvement.
• Liver transplantation for decompensated NASH cirrhosis or HCC within criteria.

Contraindicated/avoid

• Pioglitazone in heart failure, and vitamin E is not recommended in diabetes, cirrhosis, or cryptogenic cirrhosis.
• Resmetirom is not for decompensated cirrhosis.
• Ursodeoxycholic acid and metformin are not effective for NASH histology.

Hepatic complications

• Progression to NASH and bridging fibrosis: driven by sustained lipotoxicity, Kupffer cell activation, and stellate cell collagen deposition; signalled by a rising FIB-4, increasing liver stiffness on elastography, or an AST/ALT ratio that inverts to >1.
• Cirrhosis and portal hypertension: architectural distortion raises sinusoidal resistance. Heralded by thrombocytopenia (splenic sequestration), falling albumin, rising INR and bilirubin.
• Variceal hemorrhage — emergency: hematemesis or melena from portosystemic collaterals. Requires resuscitation, octreotide, prophylactic antibiotics (ceftriaxone), and urgent endoscopic band ligation.
• Spontaneous bacterial peritonitis — emergency: ascitic fluid PMN count ≥250/mm³; treat with a third-generation cephalosporin plus albumin.
• Hepatic encephalopathy — emergency if grade III–IV: ammonia-driven astrocyte swelling; asterixis is the exam finding.
• Hepatocellular carcinoma: the tested nuance is that HCC can arise in NASH without cirrhosis. Surveillance with ultrasound ± AFP every 6 months is recommended by AASLD once cirrhosis is present.
• "Cryptogenic" cirrhosis: burnt-out NASH loses its steatosis, so the histologic clue disappears.

Extrahepatic complications

• Atherosclerotic cardiovascular disease: the leading cause of death in NAFLD, exceeding liver-related mortality — a high-yield fact.
• Type 2 diabetes and chronic kidney disease: NAFLD independently predicts incident diabetes and albuminuric CKD via systemic insulin resistance and inflammation.

Treatment-related complications

• Pioglitazone: PPAR-γ-mediated renal sodium retention causes weight gain, edema, and precipitation or worsening of heart failure; also distal bone loss and fracture.
• Vitamin E: signals for increased hemorrhagic stroke and, in long-term data, prostate cancer risk in men.
• Resmetirom: diarrhea and nausea early; statin interactions require dose attention.
• GLP-1 receptor agonists: nausea, gallstone formation with rapid weight loss, pancreatitis.
• Bariatric surgery: very rapid weight loss can transiently worsen steatohepatitis, and long-term micronutrient deficiency (iron, B12, fat-soluble vitamins) is expected.

• AST/ALT ratio is the discriminator: NAFLD gives ALT > AST (ratio <1); alcohol-related liver disease gives AST:ALT ≥2:1 ("a Scotch and Tonic"). A ratio drifting above 1 in a known NAFLD patient suggests advancing fibrosis, not a new diagnosis.
• Single best next step in an obese diabetic with incidental fatty liver on ultrasound: calculate FIB-4, not order a biopsy. AASLD and the AGA pathway put non-invasive fibrosis scoring before any invasive test; elastography or ELF follows an indeterminate or high FIB-4.
• Histology buzzwords: hepatocyte ballooning degeneration, Mallory-Denk bodies, and zone 3 perisinusoidal "chicken-wire" fibrosis. These are shared with alcoholic steatohepatitis — history, not histology, separates them.
• Fibrosis stage, not the NAS, predicts liver-related and all-cause mortality. Steatosis alone is largely benign.
• The association examiners love: NAFLD is strongly linked to insulin resistance and metabolic syndrome, and the leading cause of death is cardiovascular disease, not cirrhosis. The corollary is that aggressive ASCVD risk reduction is core NAFLD care.
• Statins are safe and indicated in NAFLD/NASH including compensated cirrhosis. "Stop the statin because ALT is elevated" is the most common distractor on this topic.
• Weight loss is dose-dependent: about 5% for steatosis, 7–10% to resolve steatohepatitis, ≥10% for fibrosis regression. Vitamin E is for non-diabetic, non-cirrhotic biopsy-proven NASH; pioglitazone is contraindicated in heart failure; resmetirom (thyroid hormone receptor-β agonist) is the FDA-approved agent for noncirrhotic F2–F3 MASH.
• HCC can occur in NASH without cirrhosis — and cryptogenic cirrhosis in an obese diabetic is burnt-out NASH whose steatosis has vanished.
• Nomenclature: multi-society consensus renamed NAFLD as MASLD (metabolic dysfunction-associated steatotic liver disease), requiring at least one cardiometabolic risk factor; newer stems may use MASLD/MASH interchangeably with NAFLD/NASH.